Robbins LLP is Investigating Allegations that Lantheus Holdings, Inc. (LNTH) Misled Investors About Pylarify's Competitive Position

Robbins LLP informs stockholders that a class action was filed on behalf of persons and entities that purchased or otherwise acquired Lantheus Holdings, Inc. (NASAQ: LNTH) securities between February 26, 2025 and August 5, 2025. Lantheus is a global company that develops, manufactures, sells, and distributes certain diagnostic and therapeutic products. The Company’s key Radiopharmaceutical Oncology product is Pylarify, a PET imaging agent used to assist in both diagnosing and subsequently treating prostate cancer.

The Allegations:

According to the complaint, during the class period, defendants disseminated materially false and misleading statements concerning the true state of Pylarify’s competitive position. Specifically, that Lantheus was not equipped to properly assess the pricing and competitive dynamics for Pylarify; the Company failed to properly disclose that its early 2025 price increase, issued despite price erosion the year prior, created an opportunity for competitive pricing to flourish, risking Pylarify’s price point, revenue, and overall growth potential.

Plaintiff alleges that in truth, Lantheus’ optimistic reports of Pylarify’s sales growth potential and pricing normalization fell short of reality. Lantheus, despite defendants' claims, did not have an accurate understanding of the pricing and competitive dynamics of Pylarify’s market.

On August 6, 2025, Lantheus announced disappointing results and significantly reduced growth expectations for Pylarify, which had fallen 8.3% year-over-year, and slashed fiscal year 2025 growth projections further. Defendants again attributed the losses to the ongoing competition, impacting Pylarify’s pricing dynamics. On this news, the price of Lantheus’ common stock plummeted from $72.83 per share on August 5, 2025, to $51.87 per share on August 6, 2025, a decline of about 28.8% in the span of one day. 

What Now: You may be eligible to participate in the class action against Lantheus Holdings, Inc. Shareholders who wish to serve as lead plaintiff for the class should contact Robbins LLP by the November 10, 2025 lead plaintiff deadline. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation.  You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.